Moreover, it provides new insights that complement previous metanalytic approaches,67 by systematically standardising Lp(a) differences between CAVD patients and healthy controls and by offering additional collective evidence regarding the Lp(a)-related AVS progression acceleration and risk of serious adverse events. The gene discussed is LPA; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.